Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Mario Luca Morieri, Angelo Avogaro & Gian Paolo Fadini. (2020) Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice. Diabetes, Metabolic Syndrome and Obesity 13, pages 4221-4234.
Read now
Read now
Articles from other publishers (20)
Yifang Yang, Candy Lee, Reddy Rajasekhar Reddy, David J. Huang, Weixia Zhong, Vân T. B. Nguyen-Tran, Weijun Shen & Qing Lin. (2022) Design of Potent and Proteolytically Stable Biaryl-Stapled GLP-1R/GIPR Peptide Dual Agonists. ACS Chemical Biology 17:5, pages 1249-1258.
Crossref
Crossref
Alex Ramírez-Rincón, Carlos E. Builes-Montaño, Jaime A. Hincapié-García, Victor M. Blanco & José F. Botero-Arango. (2022) Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting. Frontiers in Endocrinology 13.
Crossref
Crossref
Kenichi Furihata, Hanaka Mimura, Shweta Urva, Tomonori Oura, Kenji Ohwaki & Takeshi Imaoka. (2021)
A phase 1 multiple‐ascending dose study of tirzepatide in
Japanese
participants with type 2 diabetes
. Diabetes, Obesity and Metabolism 24:2, pages 239-246.
Crossref
Crossref
Marco Orsini Federici, Raffaella Gentilella, Antonella Corcos, Enrico Torre & Stefano Genovese. (2021) Changing the approach to type 2 diabetes treatment: A comparison of glucagon‐like peptide‐1 receptor agonists and sulphonylureas across the continuum of care. Diabetes/Metabolism Research and Reviews 37:7.
Crossref
Crossref
Xiaoyun Yang, Qian Liu, Yuxin Fan, Li Ding, Ruodan Wang, Gang Hu & Ming Liu. (2021) Cardiovascular Risk Factor Status in Hospitalized Patients With Type 2 Diabetes in China. Frontiers in Endocrinology 12.
Crossref
Crossref
Barrie Chubb, Palvi Gupta, Jatin Gupta, Solomon Nuhoho, Klaus Kallenbach & Michelle Orme. (2021) Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis. Diabetes Therapy 12:5, pages 1325-1339.
Crossref
Crossref
Antonio C. Bossi, Valentina De Mori, Cristiana Scaranna, Giovanni Veronesi, Giuseppe Lepore, Agosti Barbara, Bellante Rosalia, Belviso Antonio, Berzi Denise, Bonfadini Silvia, Casati Sergio, Colzani Milena, Ettori Stefano, Franzetti Ivano, Gaiti Margherita, Ghilardi Giosuè, Lovati Elisabetta, Lucotti Pietro, Malighetti Maria Elena, Manzoni Giuseppina, Meregalli Giancarla, Orsi Emanuela, Palmieri Eva, Querci Fabrizio, Ragni Giorgio, Rinaldi Joselita, Severgnini Silvia Cecilia, Zenoni Luca, Bertola Davide Pietro, Buizza Mario, Calebitch Silvia, Creanza Annalisa, D’Angelo Francesco, Magri Viviana, Mantovani Linneo Enzo, Mascadri Cristina, Pagani Micol, Paroli Antonio, Richini Donata, Rignanese Giovanni & Zarra Emanuela. (2020) ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with Dulaglutide. Diabetes Therapy 11:11, pages 2677-2690.
Crossref
Crossref
Muhammad Shahzeb KhanGregg C. Fonarow, Darren K. McGuireAdrian F. HernandezMuthiah VaduganathanJulio RosenstockYehuda HandelsmanSubodh VermaStefan D. AnkerJohn J.V. McMurray, Mikhail N. KosiborodJaved Butler. (2020) Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. Circulation 142:12, pages 1205-1218.
Crossref
Crossref
Juan Pablo Frias, Michael A. Nauck, Joanna Van, Charles Benson, Ross Bray, Xuewei Cui, Zvonko Milicevic, Shweta Urva, Axel Haupt & Deborah A. Robins. (2020) Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens. Diabetes, Obesity and Metabolism 22:6, pages 938-946.
Crossref
Crossref
Melanie J. Davies, Cristina Bianchi & Stefano Del Prato. (2020) Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. Metabolism 107, pages 154242.
Crossref
Crossref
Mario Luca Morieri, Mauro Rigato, Vera Frison, Natalino Simioni, Michele D'Ambrosio, Federica Tadiotto, Agostino Paccagnella, Annunziata Lapolla, Angelo Avogaro & Gian Paolo Fadini. (2020) Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies. Metabolism 106, pages 154190.
Crossref
Crossref
Julie Holt, Anne Knox & Kimberly Williams Smith. (2020) In patients with type 2 diabetes, which GLP-1 receptor agonist results in the greatest HbA1C reduction?. Evidence-Based Practice 23:4, pages 21-23.
Crossref
Crossref
Solomon Nuhoho, Jatin Gupta, Brian Bekker Hansen, Mary Fletcher-Louis, Tam Dang-Tan & Abby Paine. (2019) Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis. Diabetes Therapy 10:6, pages 2183-2199.
Crossref
Crossref
David M. Williams, Natasha Shrikrishnapalasuriyar, Waheeba Syed, Win L. Yin, Richard Chudleigh, Stephen C. Bain, David E. Price & Jeffrey W. Stephens. (2018) Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 12:6, pages 1079-1082.
Crossref
Crossref
Lawrence Blonde & Vivian Fonseca. (2018) Glucagon-Like Peptide 1 Receptor Agonists For Type 2 Diabetes: A Comprehensive Review of How to Weigh The Options, Select the Right Patients, and Maximize Benefits. Endocrine Practice 24, pages 8-19.
Crossref
Crossref
Jodi Strong. (2018) Are there differences in the efficacy of once-weekly GLP-1RAs in patients with type 2 diabetes?. Journal of the American Association of Nurse Practitioners 30:1, pages S19-S28.
Crossref
Crossref
Clement Lo, Tadashi Toyama, Ying Wang, Jin Lin, Yoichiro Hirakawa, Min Jun, Alan Cass, Carmel M Hawley, Helen Pilmore, Sunil V Badve, Vlado Perkovic & Sophia Zoungas. (2018) Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Yehuda HandelsmanKathleen WyneAnthony CannonMichael ShannonDoron Schneider. (2018) Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. Journal of Managed Care & Specialty Pharmacy 24:9-a Suppl, pages S14-S29.
Crossref
Crossref
Michal Witkowski, Lars Wilkinson, Neil Webb, Alan Weids, Divina Glah & Hrvoje Vrazic. (2018) A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin. Diabetes Therapy 9:3, pages 1233-1251.
Crossref
Crossref
Michal Witkowski, Lars Wilkinson, Neil Webb, Alan Weids, Divina Glah & Hrvoje Vrazic. (2018) A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs. Diabetes Therapy 9:3, pages 1149-1167.
Crossref
Crossref